CULLINAN THERAPEUTICS, INC. Investment Income, Interest
CULLINAN THERAPEUTICS, INC. (CGEM) reported Investment Income, Interest of $3.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-06-30 was $3.65M, a 38.42% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-03-31 was $4.10M, a 37.72% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-12-31 was $4.62M, a 38.56% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-09-30 was $5.09M, a 39.25% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. investment income, interest for fiscal 2025 was $22.21M, a 25.11% decline from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. investment income, interest for fiscal 2024 was $29.66M, a 37.14% increase from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. investment income, interest for fiscal 2023 was $21.63M, a 227.14% increase from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. investment income, interest for fiscal 2022 was $6.61M, a 1285.95% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.65M 10-Q · filed 2026-08-06 | $7.75M 10-Q · filed 2026-08-06 | $12.36M derived: sum of 3 quarters · filed 2026-08-06 | $17.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.10M 10-Q · filed 2026-05-07 | $8.71M derived: sum of 2 quarters · filed 2026-05-07 | $13.81M derived: sum of 3 quarters · filed 2026-05-07 | $19.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $9.71M derived: sum of 2 quarters · filed 2026-03-10 | $15.63M derived: sum of 3 quarters · filed 2026-08-06 | $22.21M 10-K · filed 2026-03-10 |
| 2025-09-30 | $5.09M 10-Q · filed 2025-11-06 | $11.02M derived: sum of 2 quarters · filed 2026-08-06 | $17.60M 10-Q · filed 2025-11-06 | $25.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.92M 10-Q · filed 2026-08-06 | $12.50M 10-Q · filed 2026-08-06 | $20.02M derived: sum of 3 quarters · filed 2026-08-06 | $28.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.58M 10-Q · filed 2026-05-07 | $14.09M derived: sum of 2 quarters · filed 2026-05-07 | $22.48M derived: sum of 3 quarters · filed 2026-05-07 | $30.55M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $15.90M derived: sum of 2 quarters · filed 2026-03-10 | $23.97M derived: sum of 3 quarters · filed 2026-03-10 | $29.66M 10-K · filed 2026-03-10 |
| 2024-09-30 | $8.38M 10-Q · filed 2025-11-06 | $16.45M derived: sum of 2 quarters · filed 2025-11-06 | $22.15M 10-Q · filed 2025-11-06 | $28.07M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $8.07M 10-Q · filed 2025-08-07 | $13.76M 10-Q · filed 2025-08-07 | $19.68M derived: sum of 3 quarters · filed 2025-08-07 | $25.56M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $5.69M 10-Q · filed 2025-05-08 | $11.61M derived: sum of 2 quarters · filed 2025-05-08 | $17.49M derived: sum of 3 quarters · filed 2025-05-08 | $22.81M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $11.80M derived: sum of 2 quarters · filed 2025-02-27 | $17.12M derived: sum of 3 quarters · filed 2025-02-27 | $21.63M 10-K · filed 2025-02-27 |
| 2023-09-30 | $5.88M 10-Q · filed 2024-11-07 | $11.20M derived: sum of 2 quarters · filed 2024-11-07 | $15.71M 10-Q · filed 2024-11-07 | $19.07M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $5.32M 10-Q · filed 2024-08-08 | $9.83M 10-Q · filed 2024-08-08 | $13.19M derived: sum of 3 quarters · filed 2024-08-08 | $15.55M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.51M 10-Q · filed 2024-05-15 | $7.87M derived: sum of 2 quarters · filed 2024-05-15 | $10.22M derived: sum of 3 quarters · filed 2024-05-15 | $10.92M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $5.72M derived: sum of 2 quarters · filed 2024-03-14 | $6.41M derived: sum of 3 quarters · filed 2024-03-14 | $6.61M 10-K · filed 2024-03-14 |
| 2022-09-30 | $2.35M 10-Q · filed 2023-11-08 | $3.05M derived: sum of 2 quarters · filed 2023-11-08 | $3.25M 10-Q · filed 2023-11-08 | $3.38M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $697.00K 10-Q · filed 2023-08-10 | $894.00K 10-Q · filed 2023-08-10 | $1.03M derived: sum of 3 quarters · filed 2023-08-10 | $1.15M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $197.00K 10-Q · filed 2023-05-11 | $334.00K derived: sum of 2 quarters · filed 2023-05-11 | $452.00K derived: sum of 3 quarters · filed 2023-05-11 | $625.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $255.00K derived: sum of 2 quarters · filed 2023-03-09 | $428.00K derived: sum of 3 quarters · filed 2023-03-09 | $477.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $118.00K 10-Q · filed 2022-11-14 | $291.00K derived: sum of 2 quarters · filed 2022-11-14 | $340.00K 10-Q · filed 2022-11-14 | $419.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $173.00K 10-Q · filed 2022-08-10 | $222.00K 10-Q · filed 2022-08-10 | $301.00K derived: sum of 3 quarters · filed 2022-08-10 | $486.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $49.00K 10-Q · filed 2022-05-16 | $128.00K derived: sum of 2 quarters · filed 2022-05-16 | $313.00K derived: sum of 3 quarters · filed 2022-05-16 | $559.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $264.00K derived: sum of 2 quarters · filed 2022-03-17 | $510.00K derived: sum of 3 quarters · filed 2022-03-17 | $888.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $185.00K 10-Q · filed 2021-11-09 | $431.00K derived: sum of 2 quarters · filed 2021-11-09 | $809.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $246.00K 10-Q · filed 2021-08-10 | $624.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $378.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |